An Intermediate CBD Stress Response Was Not a Significant Placebo Difference

A CBD group’s average response can fall between placebo patients and healthy controls without demonstrating a significant CBD-versus-placebo benefit. A study of social stress in people at clinical high risk of psychosis illustrates this statistical distinction.

Stress hormones and subjective symptoms were separate endpoints

Participants at clinical high risk received 600 mg oral CBD daily or placebo, then completed a Trier Social Stress Test on day eight. A healthy comparison group completed the stress procedure without entering the drug trial.

The stress challenge combined public speaking and mental arithmetic. Investigators measured serum cortisol from blood samples, state anxiety and negative self-statements. Cortisol is a neuroendocrine measure; it is not a direct measure of psychological distress or a diagnosis of psychosis.

A significant three-group trend did not establish treatment efficacy

The study reported ordered patterns across healthy controls, CBD-treated high-risk participants and placebo-treated high-risk participants. The CBD group was intermediate on cortisol reactivity and psychological responses.

However, direct CBD–placebo comparisons were not significant for cortisol reactivity (p = 0.70) or anxiety (p = 0.36). The negative-self-statement comparison also did not reach conventional significance (p = 0.088). The authors acknowledged that the significant overall trends were largely driven by differences involving healthy controls.

Why that changes the conclusion

A comparison with a healthy reference group can help characterize a pattern. It cannot replace the randomized treatment contrast when asking whether CBD caused a clinical benefit. A value closer to the healthy mean is an observation, not automatically evidence of normalization.

The study was small, some outcome data were incomplete, and missing-data procedures and differing analysis samples require attention. A short laboratory challenge also does not establish reduced psychosis incidence or lasting improvement in everyday stress.

This report arose from the same broader research program as an acute CBD imaging report. Different endpoints and treatment durations can be informative without turning related participants into independent confirmations.

When reading a cannabis-treatment headline, identify the comparison that actually supports it. Our article on CBD outcomes and study design explains why a promising pattern and demonstrated treatment efficacy require different language.

Primary research

E. Appiah-Kusi and colleagues. Psychopharmacology (2020). Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis.